Superselective intra-arterial chemotherapy treatment for retinoblastoma: clinical experience from a tertiary referral centre.
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, cilt.55, sa.5, ss.406-412, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 55 Sayı: 5
- Basım Tarihi: 2020
- Doi Numarası: 10.1016/j.jcjo.2020.04.009
- Dergi Adı: Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.406-412
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
© 2020 Canadian Ophthalmological SocietyObjective: To evaluate the treatment outcomes of an alternative retrograde superselective ophthalmic artery catheterization (intra-arterial chemotherapy [IAC]), while treating retinoblastoma patients. Methods: A retrospective review of IAC for 21 treatment-naïve eyes (21 patients, primary group) and 10 eyes of previously treated 9 patients (secondary group). Statistical analysis was performed using Number Cruncher Statistical System 2007, Kaplan–Meier survival analysis, and Fisher's exact test. Results: Total fluoroscopy time ranged from 3 to 12 minutes. Globe salvage was 71.4% (15/21 eyes) and 80% (8/10 eyes) in the primary and secondary groups, respectively. Globe salvage rates were recorded as 100%, 100%, 70%, and 0% for group B, C, D, and E patients, respectively. Conclusions: Retrograde IAC is effective in tumour control with shorter fluoroscopy time and acceptable complication rates both for naïve and treated patients. Furthermore, controlling retinoblastoma in advanced group D eyes was efficacious.